Cytogen Inc. (217330)

Overview

Cytogen, Inc. is a pioneering biotechnology company based in Seoul, South Korea, specializing in the field of blood cancer with a focus on the utilization of cell-based Liquid Biopsy technologies. Established in 2010, the company has dedicated itself to the development and commercialization of innovative solutions aimed at enriching Circulating Tumor Cells (CTCs) from human blood and/or body fluid. Cytogen, Inc. operates under the Smart Biopsy brand name, positioning itself as a significant player in the biotechnological industry within South Korea by offering state-of-the-art products designed for enhancing cancer diagnosis and treatment monitoring.

Products and Services

• Cell Isolators

  Cytogen delivers advanced cell isolators that leverage high-density microporous chips. These devices are engineered to enrich CTCs from human blood and/or body fluid, providing a pivotal tool in the early detection and analysis of blood cancers. The precision and efficiency of these cell isolators make them an invaluable asset in the field of oncology.

• IF Stainers

  The company's IF stainers represent an automated immunofluorescent staining system. This technology is devised to stain cells with a range of antibodies, such as anti-EpCAM, -CD45, and CK antibodies, thus facilitating the accurate identification and analysis of various cancer cells. The automation of the staining process enhances reliability while minimizing the potential for human error.

• Cell Image Analyzers

  To complement its range of cell isolation and staining products, Cytogen, Inc. offers cell image analyzers. These instruments are designed to capture immunofluorescent images of the previously stained cells. By providing high-resolution images of targeted cells, these analyzers are crucial for the precise examination and quantification of cancer cells in blood and body fluids.